Skip to content
DataLookout
Menu

NCT02158091

A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL

StatusActive, Not Recruiting
PhasePhase 1/2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 24 versions: 12 with changes below, 12 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 21 words
    • Study completion pushed from Jul 2026 to Dec 2026
    • Secondary endpoints: details revised at 4 of 9 entries
  2. Minor Study completion date: Jul 2025 to Jul 2026v22
  3. Minor Study completion date: Jul 2030 to Jul 2025v18
  4. Minor Collaborator revisedv16
  5. Minor Study completion date: Jul 2021 to Jul 2030v12
Show 6 earlier versionsHide 6 earlier versions
  1. Notable Results first posted: Dec 11, 2018
    • Primary endpoints revised (2)
    • Start date: Jul 2014 to Jun 27, 2014
    • Secondary endpoints: 7 to 9
    v11
  2. Minor Collaborator revisedv9
  3. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 2 of 2 sites
    v8
  4. Minor Enrollment target: 26 to 32
    • Site details revised at 1 of 2 sites
    v7
  5. Notable Trial status: Not Yet Recruiting to Recruiting
    • Site details revised at 2 of 2 sites
    v4
  6. Notable Eligibility criteria shortened, about 434 words
    • Study title shortened, about 8 words
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of Patients Who Experienced a Dose Limiting Toxicity (DLT) During Phase I
Timeframe: . Participants were assessed every week or more often as needed during Cycle 1, and every Day 1 Cycles 2 and onward-Dose-limiting toxicities (DLTs) occurring during the first cycle of treatment will be used in determining the Phase II MTD/RP2D
Number of Patients Who Had a Minimal Residual Disease (MRD) Negative Complete Response (CR) 2 Months After Chemotherapy
Timeframe: 2 months after completion of combination therapy of IPI-145 and FCR

Secondary (9)

Overall Response Rate
Number of Participants With Serious and Non-Serious Adverse Events
Rate of Minimal Residual Disease (MRD) in the Peripheral Blood
Rate of Treatment Related Adverse Effects
Determine the Association of Established CLL Prognostic Factors With Clinical Response
Show 4 moreShow less
Rate of Complete Response and Partial Response
Rate of Progression Free Survival
Event Free Survival Rate
Duration of Remission Rate

Arms and interventions

IPI-145Experimental

Phase I-Dose escalation will occur using a standard 3-3 dose escalation beginning in dose level 1 with dose cohorts and escalation. * Each treatment cycle lasts 28 days (except cycle 1, which is 35 days) during which time IPI-145 will be taken twice daily. The study begins with 1 week of IPI-145 monotherapy. * Fludarabine, cyclophosphamide, rituximab (iFCR) - FCR will subsequently be introduced after 1 week and administered at standard dosing for up to 6 cycles, with dose reductions permitted. IPI-145 will be continued through the course of chemotherapy and for up to 2 years maintenance after completing chemotherapy Phase II - 20 additional patients treated with IPI-145 at the Recommended Phase II Dose (RP2D) + fludarabine, cyclophosphamide, rituximab (FCR) with standard dosing.

Drugs: IPI-145, Fludarabine, Cyclophosphamide, Rituximab

Sites

2 sites in 1 country